Status:
COMPLETED
Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Glaxo Wellcome
Conditions:
Pneumonia, Pneumocystis Carinii
HIV Infections
Eligibility:
All Genders
13+ years
Phase:
PHASE4
Brief Summary
To determine whether gradual initiation of sulfamethoxazole/trimethoprim (SMX/TMP) reduces the incidence of treatment-limiting adverse reactions compared to the routine initiation of the drugs for Pne...
Detailed Description
Although a number of clinical trials have demonstrated the superiority of SMX/TMP for PCP prophylaxis, the incidence of adverse reactions to this medication is high. In a pilot study in which patients...
Eligibility Criteria
Inclusion Criteria
Concurrent Medication:
Allowed if clinically indicated:
- Recombinant erythropoietin (rEPO) and G-CSF.
Allowed for symptomatic treatment of mild study drug toxicity:
- Antipyretics and analgesics (ibuprofen).
- Antihistamines (diphenhydramine HCl).
- Terfenadine or astemizole (but not allowed with concomitant antifungal or macrolide use).
- Systemic steroids.
Patients must have:
- HIV infection.
- CD4 count <= 250 cells/mm3 OR history or presence of thrush.
- No history of confirmed or probable pneumocystosis.
NOTE:
- Pregnant women are not excluded, but safety issues should be discussed with patient prior to enrollment.
- This study is appropriate for prisoner participation.
- Coenrollment in ongoing ACTG antiretroviral studies is permitted provided no new study drugs are added to the patient's drug regimen for 4 weeks before or after initiation of SMX/TMP.
Prior Medication:
Allowed:
- Prior aerosolized pentamidine and dapsone for primary PCP prophylaxis.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known adverse reactions to sulfa, trimethoprim, or SMX/TMP.
- Inability to comply with dosing schedule or complete dosing record.
Concurrent Medication:
Excluded:
- Procysteine.
- Glutathione.
- N-acetylcysteine (NAC).
- Antihistamines (unless used for symptomatic treatment of study drug toxicity).
- Systemic corticosteroids (unless used for replacement purposes).
- Leucovorin calcium (unless used for symptomatic treatment of study drug toxicity).
- TMP or sulfa drugs outside of the study.
Prior Medication:
Excluded at any time:
- Prior SMX/TMP as primary PCP prophylaxis.
Excluded within 4 weeks prior to study entry:
- Initiation of antiretroviral agents.
- Initiation of anti-infective agents (including SMX/TMP for another indication).
Excluded within 2 weeks prior to study entry:
- Antihistamines.
- Procysteine.
- Glutathione.
- N-acetylcysteine (NAC).
- Systemic corticosteroids (unless used for replacement purposes).
- Leucovorin calcium.
- TMP and sulfa drugs separately.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
September 1 1996
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT00000816
End Date
September 1 1996
Last Update
November 4 2021
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
USC CRS
Los Angeles, California, United States, 90033
2
Stanford CRS
Palo Alto, California, United States, 94305
3
Ucsf Aids Crs
San Francisco, California, United States, 94110
4
Santa Clara Valley Med. Ctr.
San Jose, California, United States